Eli Lilly Cites Subsidy Issues, Mounjaro Unavailable in Australia
Eli Lilly, a major pharmaceutical company, has publicly criticised Australia’s pharmaceutical subsidy system, stating that its popular weight-loss and diabetes drug, Mounjaro, will remain unavailable to Australian patients due to a commercial dispute with the Pharmaceutical Benefits Advisory Committee (PBAC).
The company’s statement represents a significant escalation in the ongoing debate surrounding drug pricing and access in Australia. Mounjaro, alongside its sister drug Zepbound (approved for weight management in the US), has demonstrated substantial efficacy in treating type 2 diabetes and promoting weight loss, generating considerable global demand.
Eli Lilly’s argument centres on the current PBAC process, which assesses the cost-effectiveness of new medicines before they can be listed on the Pharmaceutical Benefits Scheme (PBS), allowing patients to access them at a subsidised price. The company contends that the current framework is unsustainable and prevents Australians from accessing innovative treatments like Mounjaro.
While Eli Lilly has not detailed the specifics of the commercial disagreement, it is understood to involve the company's pricing proposals for Mounjaro and the PBAC’s assessment of its value for money within the Australian healthcare context. The PBAC’s role is to ensure that taxpayer dollars are used efficiently and that medicines listed on the PBS provide demonstrable health benefits at a reasonable cost.
The decision to withhold Mounjaro from the Australian market has sparked concerns among patient advocacy groups and healthcare professionals, who highlight the potential benefits of the drug for individuals struggling with obesity and type 2 diabetes. They argue that denying access to such treatments could exacerbate existing health challenges and place further strain on the healthcare system.
The Australian government has yet to formally respond to Eli Lilly’s criticisms, but the situation is expected to intensify the scrutiny of the PBS and its impact on pharmaceutical companies' willingness to bring new medicines to Australia. This standoff underscores the complex challenges involved in balancing innovation, affordability, and equitable access to essential medicines within the Australian healthcare system.
